Given that type II diabetes is increasing and that 50% of pregnancies are unplanned, a growing number of pregnant women will be exposed to hypoglycaemic agents during the gestational period. However, because there is concern regarding the adequacy of glycaemia control, and the potential teratogenicity of these agents, it is common practice to switch to insulin when the pregnancy is diagnosed.

Given that hypoglycaemic agents are easier to take than insulin, this study aims to, among type II diabetes women, compare the rate of glycaemia control between pregnant users of hypoglycaemic agents and pregnant users of insulin, and to compare the rate of birth defects between the same two study populations. This study is conducted within the Quebec Pregnancy Registry.

Funding source
Fonds de la Recherche en Santé du Québec (FRSQ), Réseau Québécois de Recherche sur l'Usage des Médicaments (RQRUM), Réseau FRSQ pour le bien-être des enfants.